
NA-931 Cuts Weight Without Major Muscle Loss in Mid-Stage Trial
An experimental oral medicine called NA-931 led to substantial weight loss with only modest reductions in lean mass in a randomized phase II trial. Researchers from developer Biomed Industries presented the topline results at the ObesityWeek annual meeting. The highest doses reduced body weight by 13.8% and 11.3% at week 13, compared with 1.9% on placebo. Lean mass fell by 1.7% over the same period, and nausea rates were only slightly higher than placebo. The company says it is advancing NA-931 into phase III testing. The findings are early and come from a small study of 125 adults.
